Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Ivy Rx vs Neo Soma Healthcare

Ivy Rx
Graded #178

Higher grade

vs+1
Neo Soma Healthcare
Graded #213

Lower grade

The verdict

Ivy Rx takes it — 66.8/100 to 65.8/100, but only just.

Ivy Rx grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Telehealth provider offering tiered compounded semaglutide and tirzepatide programs. Neo Soma Healthcare is close behind and may still be the better fit — see the factor split below.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueNeo Soma Healthcare +4
62
66
Dose & formulationNeo Soma Healthcare +8
64
72
Clinical oversightIvy Rx +10
82
72
Labs & monitoringNeo Soma Healthcare +9
53
62
FulfillmentIvy Rx +24
81
57
Contract termsEven
55
55
Ivy Rx · left barNeo Soma Healthcare · right bar

The numbers

MetricIvy RxNeo Soma Healthcare
WeighScore66.8/10065.8/100
GradeCC
Scorecard rank#178#213
Semaglutide$175/mo (starting dose, compounded)$199/mo
Tirzepatide$275/mo (starting dose, compounded)$330/mo
CoverageAll 50 statesCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
Ivy Rx

Graded #178 · C

Strengths

  • Both semaglutide and tirzepatide available
  • Compounded GLP-1 access

Where it loses points

  • Limited public information on program details
Neo Soma Healthcare

Graded #213 · C

Strengths

  • LegitScript verification badge present
  • Publishes the FDA compounded-medication disclaimer
  • Pricing shown publicly for all 6 product lines
  • Multi-product platform (GLP-1, sexual health, peptide therapies)
  • First-month discount on semaglutide ($99 entry)

Where it loses points

  • Pharmacy partner not named (503A vs 503B unclear)
  • States served not listed — no per-state availability table
  • No named medical director
  • Standard semaglutide pricing ($199/mo) above the cheapest providers ($150–180/mo)
  • Tirzepatide entry pricing ($330) above the cheapest providers (~$200–250/mo)

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard